Michael A. Sherman has served on Aktis Oncology's board of directors since August 2025. He previously served as Chief Executive Officer of Chimerix and, before that, as President and Chief Executive Officer of Endocyte until its acquisition by Novartis in 2018, having joined Endocyte as Chief Financial Officer and Chief Operating Officer. He currently serves on the board of Werewolf Therapeutics and holds a BA in economics from DePauw University and an MBA from the Tuck School of Business at Dartmouth.